Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Trial of PBI-05204 in Advanced Cancer Patients

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: PBI-05204

First Posted Date: 2007-11-06

Last Posted Date: 2016-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 58

Registration Number: NCT00554268

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

Phase 3

Completed

Conditions: Chemotherapy-induced Nausea and Vomiting
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: dexamethasone
Drug: dronabinol
Drug: palonosetron hydrochloride
Other: placebo

First Posted Date: 2007-11-04

Last Posted Date: 2020-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT00553059

Locations: 🇺🇸
University of Texas M.D. Anderson, Houston, Texas, United States
🇺🇸
CCOP - Greenville, Greenville, South Carolina, United States
🇺🇸
Cancer Research for the Ozarks, Springfield, Missouri, United States

and more 1 locations

Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy

Phase 3

Completed

Conditions: Brain Cancer

Interventions: Other: Observation
Procedure: Whole Brain Radiation Therapy
Behavioral: Questionnaire

First Posted Date: 2007-10-24

Last Posted Date: 2023-06-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 152

Registration Number: NCT00548756

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bevacizumab in Multiple Phase I Combinations

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Bevacizumab
Drug: Sunitinib
Drug: Sorafenib
Drug: Erlotinib
Drug: Trastuzumab
Drug: Cetuximab
Drug: Lapatinib

First Posted Date: 2007-10-15

Last Posted Date: 2020-06-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 343

Registration Number: NCT00543504

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Phase 1

Completed

Conditions: Rectal Cancer

Interventions: Drug: Bevacizumab
Drug: Capecitabine
Drug: Erlotinib
Radiation: Radiation Therapy
Procedure: Surgery

First Posted Date: 2007-10-15

Last Posted Date: 2015-02-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00543842

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease

Phase 1

Completed

Conditions: Liver Cancer

Interventions: Diagnostic Test: Magnetic Resonance Elastogram
Diagnostic Test: 2-Point Dixon Magnetic Resonance Imaging

First Posted Date: 2007-10-15

Last Posted Date: 2021-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT00543777

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer

Interventions: Drug: Sorafenib
Procedure: Radiation Therapy

First Posted Date: 2007-10-12

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00543335

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States

The Exceptional Patient in Cancer Care

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: Interview

First Posted Date: 2007-10-12

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00543153

Locations: 🇮🇱
Tel Aviv University, Tel Aviv, Israel
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
AML
Myelodysplastic Disorders

Interventions: Drug: Idarubicin
Drug: Sorafenib
Drug: Ara-C

First Posted Date: 2007-10-12

Last Posted Date: 2018-08-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT00542971

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Procedure: Paravertebral Block
Drug: Propofol
Drug: Ropivacaine
Drug: Fentanyl
Drug: Midazolam

First Posted Date: 2007-10-11

Last Posted Date: 2015-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 89

Registration Number: NCT00542542

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy